Sanofi-GSK's Beta-Containing COVID-19 Vaccine Shows Efficacy Against Omicron

Sanofi SA SNY and GSK plc GSK have announced positive data from their vaccine trial of adjuvanted bivalent D614 and Beta (B.1.351) vaccine candidate.
"Sanofi-GSK's vaccine is the first candidate to demonstrate efficacy in a placebo-controlled trial in an environment of high Omicron variant circulation," Sanofi said in a statement.
The bivalent vaccine targets the beta variant and the original strain of the virus.
Related: Sanofi-GSK's Next-Gen COVID-19 Booster Shows Potential Against Variants Of Concern.
In a trial involving 13,000 adults, the vaccine demonstrated an efficacy rate of 64.7% against symptomatic COVID and 72% against infections specifically caused by the omicron variant.
When used in people who previously had COVID, the results were stronger. The vaccine generated an efficacy rate of 75.1% against symptomatic COVID and 93.2% in omicron-confirmed symptomatic cases.
The new data supporting the bivalent vaccine will be submitted to regulatory authorities.
Sanofi and GSK's original COVID-19 vaccine is already under review by the European Medicines Agency.
Price Action: SNY shares are up 3.27% at $52.07, and GSK stock is up 1.01% at $43.18 during the premarket session on the last check Friday.
Photo by Gerd Altmann from Pixabay